Vanda Pharmaceuticals (VNDA) Capital Leases (2024 - 2026)

Vanda Pharmaceuticals has reported Capital Leases for 3 years, with the latest figure at $3.8 million in Q1 2026.

• Quarterly Capital Leases rose 28.44% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (up 28.44% YoY) and the FY2025 annual result came in at $4.1 million, up 29.56% from the prior year.
• Capital Leases declined to $3.8 million in Q1 2026 per VNDA's latest filing, from $4.1 million in the prior quarter.
• Over five years, Capital Leases peaked at $4.1 million in Q4 2025 and troughed at $2.8 million in Q3 2025.
• A 3-year average of $3.3 million and a median of $3.1 million in 2024 frame the typical range for Capital Leases.
• The sharpest annual moves came in 2025 and 2026: Capital Leases increased 29.56% in 2025, then gained 28.44% in 2026.
• Over 3 years, Capital Leases stood at $3.1 million in 2024, then advanced by 29.56% to $4.1 million in 2025, then fell by 7.14% to $3.8 million in 2026.
• According to Business Quant data, Capital Leases over the past three periods registered $3.8 million, $4.1 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.